Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial
Letter
[키워드] 1:1
Ability
Ability to walk
Activation
adhere
administer
ambulatory patient
anatomical
Anticoagulant treatment
anticoagulation
antiplatelet
Atrial fibrillation
baseline
bleeding
Blinding
block size
body temperature
calculated
Cardiovascular events
characterized
Chemotherapy
clearance
clinical benefit
clinically
Coagulation
Coagulopathy
Comorbidity
Comparator group
conducted
contraindication
control group
coronary syndrome
coronavirus
cough
COVID-19
creatinine
criteria
Critical
current
death
defined
diagnosed
diagnosed with COVID-19
Diagnosis
Disseminated intravascular coagulation
dissemination
dose
Efficacy
elderly
element
eligibility criteria
eligible
enoxaparin
enrolment
event
event rate
experimental group
Face mask
FIVE
fixed
heart failure
help
heparin-induced thrombocytopenia
Hospitalization
hospitals
hygiene
hypersensitivity
impairment
IMPROVE
In-hospital
Inflammation
information
injection
inoperable
Intervention
intervention group
invasive
Ischemia
Laboratory
lack
Last
Liver disease
lower limb
major bleeding
malignancy
multicentre
Myocardial
number
objective
Older
Open-label
outcome
parameter
participant
Participation
Patient
performed
Platelet
Positive test
Presence
prevention
protocol
provided
Radiotherapy
randomised
randomised controlled trial
randomization
randomization ratio
Randomized
Randomized controlled trial
receive
reduce
renal
respiratory symptom
resulting
risk factor
Sample size
SARS-CoV2
secondary
Seven
Shortness of breath
sore throat
Spinal cord injury
status
Stratified randomization
stroke
Study protocol
Support
surgical
survival
symptomatic
the patient
therapy
Thromboprophylaxis
thrombosis
total sample size
Transport
trauma
Travel
treated
Treatment
undergo
university
university hospital
Venous Thromboembolism
vessel
viral disease
VTE
website
[DOI] 10.1186/s13063-020-04678-4 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04678-4 PMC 바로가기 [Article Type] Letter